Pramipexole, a potent dopamine agonist, plays a vital role in managing Parkinson's disease and restless legs syndrome. Its efficacy and safety are directly linked to the quality of its synthesis, which heavily relies on the purity and consistent supply of its precursor intermediates. Among these, 2,6-Diamino-4,5,6,7-tetrahydrobenzothiazole (CAS 106006-83-1) stands out as a critical chemical component. Understanding its role and properties is essential for professionals in the pharmaceutical and chemical industries.

Chemical Profile and Significance

2,6-Diamino-4,5,6,7-tetrahydrobenzothiazole is characterized by its molecular formula C7H11N3S and a molecular weight of 169.24700. Typically appearing as a white powder, this compound possesses specific physical and chemical properties such as a density of 1.313 g/cm³, a boiling point of 359ºC at 760 mmHg, and a flash point of 170.9ºC. These attributes are important for handling, storage, and reaction conditions during synthesis. Its primary significance lies in its function as a direct intermediate in the production pathway of Pramipexole and its dihydrochloride salt. Sourcing this intermediate reliably, with assured purity and specifications, is a non-negotiable step for manufacturers aiming to produce high-grade Pramipexole.

Manufacturing and Supply Chain Considerations

For pharmaceutical manufacturers, the procurement of 2,6-Diamino-4,5,6,7-tetrahydrobenzothiazole involves careful selection of suppliers. Companies looking to buy this compound often search for terms like 'CAS 106006-83-1 price' or 'pramipexole intermediate supplier.' The ability of a manufacturer to provide consistent quality, documented purity (≥99%), and timely delivery is paramount. Many global pharmaceutical production hubs, including China, offer competitive sourcing options for this intermediate. A reliable supplier will not only provide the chemical itself but also essential documentation like CoAs, MSDS, and potentially, information on the synthetic route.

The Impact on Therapeutic Outcomes

The meticulous synthesis of Pramipexole from intermediates like 2,6-Diamino-4,5,6,7-tetrahydrobenzothiazole directly impacts the therapeutic outcome for patients. Any deviations in the intermediate's quality can lead to impurities in the final drug, potentially affecting its efficacy and safety profile. Therefore, pharmaceutical companies prioritize suppliers who demonstrate rigorous quality control and a commitment to producing intermediates that meet pharmaceutical standards. This vigilance ensures that the final Pramipexole product effectively modulates dopamine receptors to alleviate symptoms of neurological disorders.

In summary, 2,6-Diamino-4,5,6,7-tetrahydrobenzothiazole is more than just a chemical compound; it is a foundational element in the creation of essential medications. Its careful synthesis and the selection of dependable manufacturers and suppliers are critical steps that underpin the quality and availability of treatments for debilitating conditions like Parkinson's disease.